Pharmacoeconomic evaluation of pramipexole extended release monotherapy in early Parkinson’s disease
Objective. Health economic expertise of pramipexole extended release monotherapy at early stages of Parkinson’s disease. Methods. An economic model was developed based on clinical studies to derive comparative information on the effectiveness, utility and direct medical costs of antiparkinsonian tre...
Main Authors: | D. Yu. Belousov, E. V. Afanasyeva |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2018-05-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/8 |
Similar Items
-
Фармакоэкономический анализ применения противопаркинсонических препаратов в режиме монотерапии на ранних стадиях болезни Паркинсона
Published: (2018-06-01) -
Результаты проведения фармакоэкономических анализов при лечении болезни Паркинсона агонистом дофаминовых рецепторов Мирапексом
Published: (2018-06-01) -
Pharmacoeconomic analysis of Actemra<sup>®</sup> in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy
by: S. K. Zyryanov, et al.
Published: (2018-05-01) -
Pharmacoeconomic analysis of Cocarnit® complex as treatment for diabetic polyneuropathy
by: D. Yu. Belousov, et al.
Published: (2018-05-01) -
Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke
by: A. E. Cheberda, et al.
Published: (2018-05-01)